As of May 22
| +0.07 / +1.21%|
The 6 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 7.50, with a high estimate of 12.00 and a low estimate of 4.00. The median estimate represents a +27.77% increase from the last price of 5.87.
The current consensus among 7 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.